This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Empliciti
  • /
  • Phase III Study of Lenalidomide and Dexamethasone ...
Clinical trial

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

Read time: 1 mins
Last updated:30th Apr 2011

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS)

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma
Estimated Enrollment: 750
Study Start Date: May 2011
Estimated Study Completion Date: July 2019
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)

- Active Comparator:
Lenalidomide + Dexamethasone
- Experimental: Lenalidomide + Dexamethasone + Elotuzumab

Category Value
Study start date 2011-05-01

View full details